

## Attachment 9 - WCRS Data Definitions 2018

### Data Items Available for Research Requests Upon Approval (Data items must be justified in the research proposal)

<b>Data Items (Case Level)</b>	<b>NAACCR Item Number</b>	<b>Years Data Are Available</b>	<b>Comments</b>
WCRS Patient ID	20	1995-2015	WCRS Patient-Level unique identifier
WCRS Tumor ID	n/a	1995-2015	WCRS Tumor-Level unique identifier
City - (Residence at Diagnosis)	70	1995-2015	
State - (Residence at Diagnosis)	80	1995-2015	WI residents only
County - (Residence at Diagnosis)	90	1995-2015	
Zip Code - (Residence at Diagnosis)	100	1995-2015	
Census Tract	135	1995-2015	US Census Bureau Definitions
Race	160	1995-2015	US Census Bureau Definitions
Spanish/Hispanic Origin	191	1995-2015	Combines self reported with ethnicity determined by NAACCR NHIA algorithm
Sex	220	1995-2015	
Age at Diagnosis	230	1995-2015	
Birth Date	240	1995-2015	
Birthplace	250	1995-2011	Numeric code combining birth state and birth country
Birth State	252	2012-2015	US Postal alpha code
Birth Country	254	2012-2015	Alpha Code for Country (if not USA)

<b>Data Items (Case Level)</b>	<b>NAACCR Item Number</b>	<b>Years Data Are Available</b>	<b>Comments</b>
Sequence Number	380	1995-2015	Identifies the sequence of tumors recorded in the central cancer registry for the same person
Date of Diagnosis	390	1995-2015	
Primary Site	400	1995-2015	ICD-O3 coding
Laterality	410	1995-2015	This field is used to determine the number of primary cancers for a patient, for lateral sites.
Histology	522	1995-2015	ICD-O3 morphology code
Behavior	523	1995-2015	3 = malignant, 2 = in situ, 0-1 = benign/borderline (for CNS and Brain tumors only)
Grade	440	1995-2015	histologic grade, cell differentiation
Diagnostic Confirmation	490	1995-2015	Clinical or pathologic confirmation of the cancer
SEER Summary Stage	759, 760, 3020	1995-2015	WCRS combination of SEER Summary Stage 77, 2000 and CS Derived Summary Stage (most complete code used)
Treatment Status Summary	1285	2010-2015	First course treatment provided, not provided or unknown (also contains information on watchful waiting for prostate cancer)
Date Treatment Started	1260	1995-2015	Earliest date when first course cancer-directed treatment began
Surgery of Primary Site	1290	1995-2015	FORDS site-specific surgery code
Reason for No Surgery	1340	1995-2015	Examples include patient refused, surgery contraindicated, not part of planned first course, etc.
Radiation	1570	1995-2015	Type of radiation provided
Chemotherapy	1390	1995-2015	Single agent or multi agent
Hormone	1400	1995-2015	

<b>Data Items (Case Level)</b>	<b>NAACCR Item Number</b>	<b>Years Data Are Available</b>	<b>Comments</b>
Immunotherapy (BRM)	1410	1995-2015	
Transplant or Endocrine Surgery	3250	2004-2015	This field indicates if the patient received a bone marrow transplant or endocrine surgery
Surgery/Radiation Treatment Sequence	1380	1995-2015	If both surgery and radiation were performed, this field identifies which came first.
Surgery/Systemic Treatment Sequence	1639	1995-2015	If both surgery and systemic rx given (chemo, immunotherapy, hormone, transplant or endocrine surgery), this field identifies which came first.
Other Cancer-Directed Treatment	1420	1995-2015	Reserved for nontraditional cancer-directed treatment (patient enrolled in clinical trial, for example).
Date of Last Contact (Date of Death)	1750	1995-2015	If patient is deceased = date of death. If patient is alive = date of last known contact with the patient by any facility
Vital Status	1760	1995-2015	1 = alive, 0 = deceased
Cause of Death	1910	1995-2015	For deaths prior to 1999 = ICD-9 codes. For deaths 1999 and later = ICD-10 codes
Last Name	2230	1995-2015	
First Name	2240	1995-2015	
Middle Name	2250	1995-2015	
Maiden Name	2390	1995-2015	
Street Address at Diagnosis	2330	1995-2015	
CS Tumor Size	2800	2004-2015	Records the size of the tumor (largest dimension) in millimeters

<b>Data Items (Case Level)</b>	<b>NAACCR Item Number</b>	<b>Years Data Are Available</b>	<b>Comments</b>
CS Extension	2810	2004-2015	Tumor extent at diagnosis by size, depth or spread (site specific coding)
CS Tumor Size/Extension Evaluation Code	2820	2004-2015	Describes if the tumor size/extent was determined clinically or pathologically
CS Lymph Nodes	2830	2004-2015	Involvement of regional lymph nodes at diagnosis (site specific coding)
CS Lymph Nodes Evaluation Code	2840	2004-2015	Describes if the status of lymph node spread was determined clinically or pathologically
CS Metastases at Diagnosis	2850	2004-2015	Describes metastases at diagnosis (site specific coding)
CS Metastases at Diagnosis Evaluation Code	2860	2004-2015	Describes if metastases was clinically or pathologically determined
Site Specific Factors 1 - 11, 13 - 17	2861-2930	2004-2015	Only available for some sites and diagnosis years; see SSF Worksheet for details by site and diagnosis year

**Site Specific Factors by Site Schema, Site Specific Factor Definition and Years Available**

Site Schema	SSF1	SSF2	SSF3	SSF4	SSF5	SSF6
<b>Appendix</b>		Clinical Assess of Regional LNs 2011-2015				
<b>Brain, CNS, Intracranial Gland</b>	WHO Grade Classification 2011-2015					
<b>Bladder</b>		Size of Mets in LNs 2011-2015				
<b>Breast</b>	ER 2010-2015	PR 2010-2015	Pos Ipsilateral Nodes 2011-2015	IHC of LNs 2011-2015	MOL of LNs 2011-2015	
<b>Conjunctiva</b>	Tumor Size 2011-2015					
<b>Corpus</b>		Peritoneal Cytology 2010-2015				
<b>Epiglottis</b>	Size of LNs 2011-2015					
<b>Esophagus</b>	Clinical Assess of Regional LNs 2011-2015					Mitotic Count (GIST) 2011-2015

**Site Specific Factors by Site Schema, Site Specific Factor Definition and Years Available**

Site Schema	SSF7	SSF8	SSF9	SSF10	SSF11	SSF13
<b>Appendix</b>					Histiopathic Grading 2011-2015	
<b>Brain, CNS, Intracranial Gland</b>						
<b>Bladder</b>						
<b>Breast</b>		HER2 IHC Lab Value 2010-2015	HER2 IHC Interpretation 2010-2015		HER2 FISH Interpretation 2010-2015	HER2 CISH Interpretation 2010-2015
<b>Conjunctiva</b>						
<b>Corpus</b>					Histiopathic Grading 2011-2015	
<b>Epiglottis</b>						
<b>Esophagus</b>						

**Site Specific Factors by Site Schema, Site Specific Factor Definition and Years Available**

Site Schema	SSF14	SSF15	SSF16	SSF17
<b>Appendix</b>				
<b>Brain, CNS, Intracranial Gland</b>				
<b>Bladder</b>				
<b>Breast</b>	Other HER2 test results 2010-2015	HER2 Summary 2010-2015	ER/PR/HER2 combo code 2010-2015	
<b>Conjunctiva</b>				
<b>Corpus</b>				
<b>Epiglottis</b>				
<b>Esophagus</b>				

**Site Specific Factors by Site Schema, Site Specific Factor Definition and Years Available**

Site Schema	SSF1	SSF2	SSF3	SSF4	SSF5	SSF6
<b>Heart</b>	Grade for Sarcomas 2011-2015					
<b>Lip, Oral Cavity and Pharynx</b>	Size of LNs 2011-2015					
<b>Lung</b>	Separate Tumor Nodules - Ipsilateral Lung 2010-2015					
<b>Lymphoma</b>		Symptoms @ Diagnosis 2011-2015				
<b>Mediastinum</b>	Grade for Sarcomas 2011-2015					
<b>Melanoma of the Skin</b>	Thickness-Depth 2011-2015	Ulceration 2011-2015	Clinical Status of LN Mets 2011-2015	LDH 2011-2015		
<b>Mycosis Fungoides</b>	Peripheral Blood Involvement 2011-2015					
<b>Peritoneum and Retroperitoneum</b>	Grade for Sarcomas 2011-2015					

**Site Specific Factors by Site Schema, Site Specific Factor Definition and Years Available**

Site Schema	SSF7	SSF8	SSF9	SSF10	SSF11	SSF13
Heart						
Lip, Oral Cavity and Pharynx						
Lung						
Lymphoma						
Mediastinum						
Melanoma of the Skin	Mitotic count/Rate 2011-2015					
Mycosis Fungoides						
Peritoneum and Retroperitoneum						

**Site Specific Factors by Site Schema, Site Specific Factor Definition and Years Available**

Site Schema	SSF14	SSF15	SSF16	SSF17
Heart				
Lip, Oral Cavity and Pharynx				
Lung				
Lymphoma				
Mediastinum				
Melanoma of the Skin				
Mycosis Fungoides				
Peritoneum and Retroperitoneum				

**Site Specific Factors by Site Schema, Site Specific Factor Definition and Years Available**

Site Schema	SSF1	SSF2	SSF3	SSF4	SSF5	SSF6
<b>Pleura</b>	Pleural Effusion 2004-2015					
<b>Prostate</b>	PSA Lab Value 2011-2015		Pathologic CS Extension 2004-2015			
<b>Retinoblastoma</b>	Extension Eval @ Enucleation 2010-2015					
<b>Soft Tissue</b>	Grade for Sarcomas 2011-2015					
<b>Testis</b>				Radical Orchiectomy Performed 2011-2015	Size of Mets in LNs 2011-2015	
<b>Vulva</b>						

**Site Specific Factors by Site Schema, Site Specific Factor Definition and Years Available**

Site Schema	SSF7	SSF8	SSF9	SSF10	SSF11	SSF13
Pleura						
Prostate		Gleason Score on Needle Core Bx 2011-2015			Gleason Score on Prostatectomy 2011-2015	
Retinoblastoma						
Soft Tissue						
Testis						Post Orchiectomy AFP Range 2011-2015
Vulva					Laterality of Regional LNs 2011-2015	

**Site Specific Factors by Site Schema, Site Specific Factor Definition and Years Available**

Site Schema	SSF14	SSF15	SSF16	SSF17
Pleura				
Prostate				
Retinoblastoma				
Soft Tissue				
Testis		Post Orchiectomy hCG 2011-2015	Post Orchiectomy LDH 2011-2015	Extranodal Extension of Regional LNs 2011-2015
Vulva				

1. Complete definitions of each variable listed (except those fields without a NAACCR Item Number) can be found at:  
North American Assoc. of Central Cancer Registries, Data Standards and Data Dictionary, Volume II, Twentieth Edition, Version 16  
<https://www.naaccr.org/data-standards-data-dictionary/>  
WCRS Coding Manual Data Dictionary  
<https://www.dhs.wisconsin.gov/publications/p0/p00832-chapter5.pdf>
2. Cases reported solely to WCRS by VA facilities are not included in any individual record level request; the MOU WCRS has with VA facilities does not allow for that type of data release.
3. Cases reported solely to WCRS by out of state cancer registries are not included in any individual record level request; the MOU WCRS has with out of state facilities does not allow for that type of data release. Inquiries can be made directly to the out of state cancer registry to receive permission for WCRS to release the data for the purpose of the study.
4. Death certificate only cases (DCOs) are not included in any individual record level request as these cases are not confirmed by any medical source.